NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on advancing surgical solutions for neurological disorders, will report its fiscal third quarter 2026 financial results before market open on Thursday, August 13, 2026. The announcement was made via a press release on August 3, 2026.
The company’s management will host an investor conference call and webcast at 8:30 a.m. Eastern time on the same day to discuss the financial results, provide a corporate update, and answer questions from participants. The call will be accessible via toll-free dial-in at 888-506-0062 for U.S. callers, or international dial-in at 973-528-0011, using participant access code 549778. A live webcast will also be available through the provided link, and participants are encouraged to join at least five minutes prior to the start to ensure timely access.
For those unable to participate live, a replay will be available through Thursday, August 27, 2026, by calling 877-481-4010 (U.S.) or 919-882-2331 (international) with passcode 54304. Additionally, a webcast replay will be accessible via the same webcast link until August 13, 2027.
This earnings announcement comes at a pivotal time for NeuroOne, which markets a portfolio of FDA-cleared products including the Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System for the brain, and OneRF® Trigeminal Nerve Ablation System. These technologies are designed to enhance diagnostic and therapeutic capabilities, potentially reducing the number of hospitalizations and surgical procedures, lowering costs, and improving patient outcomes. The company is also actively engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs, indicating a broader strategic expansion into adjacent neurological and pain management markets.
Investors and industry observers will be keen to hear updates on the commercial adoption of NeuroOne’s existing products, any progress in its pipeline, and the company’s financial trajectory. The call will provide insights into operational performance and strategic priorities, which are critical for assessing the company’s position in the competitive neurotechnology landscape.
For more information about NeuroOne and its technologies, visit the company’s website at nmtc1.com.
